SCHEMBL501561

SCHEMBL501561

COc1ccc(CNc2nc(Cl)cc(Cn3c(C(=O)c4cc(C)cc(C#N)c4)c(C(C)C)c(=O)[nH]c3=O)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 5/20 0.39
GRIN1 Q05586 2/20 0.36
GRIN2B Q13224 2/20 0.36
GSK3B P49841 1/20 0.35
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
POLB P06746 1/20 0.33
PROKR1 Q8TCW9 1/20 0.33
DYRK1A Q13627 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
BRD4 O60885 1/20 0.33
PIK3R1 P27986 1/20 0.33
PIK3CA P42336 1/20 0.33
PDE5A O76074 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL501809 0.90 VNN1 (0.37) VNN1GRIN1GRIN2BGSK3BALDH1A1
SCHEMBL10204638 0.85 GRIN1 (0.38) VNN1GRIN1GRIN2BGSK3BALDH1A1
SCHEMBL10204810 0.84 VNN1 (0.38) VNN1GRIN1GRIN2BGSK3BALDH1A1
SCHEMBL501833 0.83 KDM4E (0.32) ALDH1A1KDM4EHPGD
SCHEMBL501363 0.83 VNN1 (0.37) VNN1GRIN1GRIN2BGSK3BPOLB
SCHEMBL501655 0.82 VNN1 (0.37) VNN1GRIN1GRIN2BGSK3BALDH1A1
SCHEMBL501864 0.82 TP53 (0.37) ALDH1A1KDM4EPOLBMAPTMEN1
SCHEMBL14292830 0.82 MEN1 (0.31) ALDH1A1KDM4EMEN1KMT2AHPGD
SCHEMBL501382 0.80 TP53 (0.36) VNN1ALDH1A1KDM4EPOLBMAPT
SCHEMBL12752412 0.80 CYP3A4 (0.45) GSK3BALDH1A1KDM4EPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106064-B2 administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-01-31 US disclosed
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2010-02-11 US disclosed
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS POLR2E, POLRMT, POLR2H VNN1 1614/4885GRIN1 2439/4885GRIN2B 2882/4885
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors POLR2E, POLRMT, POLR2H VNN1 1673/4885GRIN1 2377/4885GRIN2B 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.